On this Rare Disease Day, learn more about how biosimilars are poised to help treat patients with rare diseases.
On this Rare Disease Day, learn more about how biosimilars are poised to help treat patients with rare diseases.
Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points
August 24th 2022Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.
2 Clarke Drive
Cranbury, NJ 08512